Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia
Open Access
- 15 May 2012
- journal article
- Published by Springer Nature in BMC Microbiology
- Vol. 12 (1) , 73
Abstract
Background: Recent studies suggest that the reported protective effects of statins (HMG-CoA reductase inhibitors) against community-acquired pneumonia (CAP) and sepsis in humans may be due to confounders and a healthy user-effect. To directly test whether statins are protective againstStreptococcus pneumoniae, the leading cause of CAP, we examined the impact of prolonged oral simvastatin therapy at physiologically relevant doses in a mouse model of pneumococcal pneumonia. BALB/c mice were placed on rodent chow containing 0 mg/kg (control), 12 mg/kg (low simvastatin diet [LSD]; corresponds to 1.0 mg/kg/day), or 120 mg/kg (high simvastatin diet [HSD]; corresponds to 10 mg/kg/day) simvastatin for four weeks, infected intratracheally withS. pneumoniaeserotype 4 strain TIGR4, and sacrificed at 24, 36, or 42 h post-infection for assessment of lung histology, cytokine production, vascular leakage and edema, bacterial burden and bloodstream dissemination. Some mice received ampicillin at 12-h intervals beginning at 48 h post-infection and were monitored for survival. Immunoblots of homogenized lung samples was used to assess ICAM-1 production.Results: Mice receiving HSD had reduced lung consolidation characterized by less macrophage and neutrophil infiltration and a significant reduction in the chemokines MCP-1 (P = 0.03) and KC (P = 0.02) and ICAM-1 in the lungs compared to control mice. HSD mice also had significantly lower bacterial titers in the blood at 36 (P = 0.007) and 42 (P = 0.03) hours post-infection versus controls. LSD had a more modest effect againstS. pneumoniaebut also resulted in reduced bacterial titers in the lungs and blood of mice after 42 h and a reduced number of infiltrated neutrophils. Neither LSD nor HSD mice had reduced mortality in a pneumonia model where mice received ampicillin 48 h after challenge.Conclusions: Prolonged oral simvastatin therapy had a strong dose-dependent effect on protection againstS. pneumoniaeas evidenced by reduced neutrophil infiltration, maintenance of vascular integrity, and lowered chemokine production in the lungs of mice on HSD. Statin therapy also protected through reduced bacterial burden in the lungs. Despite these protective correlates, mortality in the simvastatin-receiving cohorts was equivalent to controls. Thus, oral simvastatin at physiologically relevant doses only modestly protects against pneumococcal pneumonia.Keywords
This publication has 35 references indexed in Scilit:
- Simvastatin is Protective During Staphylococcus aureus PneumoniaCurrent Pharmaceutical Biotechnology, 2011
- Tissue‐Specific Contributions of Pneumococcal Virulence Factors to PathogenesisThe Journal of Infectious Diseases, 2004
- Prior Statin Therapy Is Associated With a Decreased Rate of Severe SepsisCirculation, 2004
- Cerivastatin ameliorates high insulin-enhanced neutrophil–endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activationJournal of Diabetes and its Complications, 2003
- Neutrophils and acute lung injuryCritical Care Medicine, 2003
- Systemic cytokine levels in community-acquired pneumonia and their association with disease severityEuropean Respiratory Journal, 2002
- Complete Genome Sequence of a Virulent Isolate of Streptococcus pneumoniaeScience, 2001
- Hospital-Acquired PneumoniaChest, 2001
- Cerivastatin Suppresses Lipopolysaccharide-Induced ICAM-1 Expression through Inhibition of Rho GTPase in BAECBiochemical and Biophysical Research Communications, 2000
- Effects of Fluvastatin on Leukocyte–Endothelial Cell Adhesion in Hypercholesterolemic RatsArteriosclerosis, Thrombosis, and Vascular Biology, 1997